Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000999060 | SCV001155464 | uncertain significance | not provided | 2023-09-01 | criteria provided, single submitter | clinical testing | VPS13B: PM2 |
Invitae | RCV001243240 | SCV001416385 | likely benign | Cohen syndrome | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000999060 | SCV001794201 | uncertain significance | not provided | 2021-01-25 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002549117 | SCV003527230 | uncertain significance | Inborn genetic diseases | 2022-02-14 | criteria provided, single submitter | clinical testing | The c.4399T>A (p.S1467T) alteration is located in exon 29 (coding exon 28) of the VPS13B gene. This alteration results from a T to A substitution at nucleotide position 4399, causing the serine (S) at amino acid position 1467 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003411944 | SCV004114960 | uncertain significance | VPS13B-related disorder | 2024-02-01 | criteria provided, single submitter | clinical testing | The VPS13B c.4324T>A variant is predicted to result in the amino acid substitution p.Ser1442Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.11% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Natera, |
RCV001243240 | SCV002082541 | uncertain significance | Cohen syndrome | 2019-10-29 | no assertion criteria provided | clinical testing |